Astex

Communities to Recognize Cancer Survivors, Raise Awareness on 35th Annual National Cancer Survivors Day

Retrieved on: 
수요일, 5월 25, 2022
People, National Cancer Survivors Day, Employment, Cancer survivor, Education, Disease, History, Population, Celebration of Life, Social media, City, Foundation, AbbVie, Insurance, Survivor, Quality of life, American Cancer Society, Caregiver, NCSD, Research, Astex, Awareness, Pembrokeshire Action To Combat Hardship, ConvaTec, Hospital, GE Healthcare, Friends, Diagnosis, Life insurance, Cancer, Instagram, Twitter, Life

FRANKLIN, Tenn., May 25, 2022 /PRNewswire-PRWeb/ -- With nearly 17 million people living with and beyond cancer in the U.S. today – and more than 43 million cancer survivors worldwide – everyone knows someone whose life has been touched by cancer. On Sunday, June 5, 2022, people around the world are coming together to acknowledge these cancer survivors, and to raise awareness of the challenges of cancer survivorship, as part of the 35th annual National Cancer Survivors Day®.

Key Points: 
  • As part of the 35th annual National Cancer Survivors Day Celebration of Life, cancer survivors and their supporters around the world will unite on Sunday, June 5, 2022, to recognize cancer survivors, raise awareness of the ongoing challenges cancer survivors face, and celebrate life.
  • On Sunday, June 5, 2022, people around the world are coming together to acknowledge these cancer survivors, and to raise awareness of the challenges of cancer survivorship, as part of the 35th annual National Cancer Survivors Day.
  • The nonprofit National Cancer Survivors Day Foundation offers free guidance, education, networking resources, and assistance to hundreds of hospitals, support groups, and other cancer-related organizations that host official National Cancer Survivors Day celebrations.
  • #NCSD2022
    The nonprofit National Cancer Survivors Day Foundation offers free guidance, education, networking resources, and assistance to hundreds of hospitals, support groups, and other cancer-related organizations that host National Cancer Survivors Day events in their communities.

Isomorphic Labs Announces First Phase of Management Team

Retrieved on: 
목요일, 5월 12, 2022
Software, Research, Pharmaceutical, Technology, Infectious Diseases, Clinical Trials, Science, Biotechnology, Other Technology, FDA, Other Science, Health, People, Food, The People's Operator, Royal Society, Ontario Institute for Cancer Research, Heidelberg University, Nature, Compliance, Rising Production, University, University of Leicester, Sophia, Breast, Drug discovery, Amazon, Oxford Brookes University, Sophia Genetics, Machine learning, GPCR, Biology, EMBL, DeepMind, Pan-Cancer Analysis, Algorithm, Research, Biophysics, Technical Working Groups, Ribociclib, Mathematics, Royal, AlphaFold, RSC, Google, Chemistry, Doctor of Philosophy, Risk, Science, University of Cambridge, FDA, Toronto, GENETICS, Publication, Engineering, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Deep learning, Technical, Astex, GlaxoSmithKline, G protein-coupled receptor, Drug development, Drug, Protein folding, CEO, Pharmaceutical industry, Medical device, Management, Alphabet, AI

Isomorphic Labs, a subsidiary of Alphabet, today announced the first phase of its management team.

Key Points: 
  • Isomorphic Labs, a subsidiary of Alphabet, today announced the first phase of its management team.
  • Isomorphic Labs mission is to use AI and machine learning methods to accelerate and improve the drug discovery process.
  • The new leaders join founder and acting CEO Demis Hassabis, who is currently serving as CEO of both DeepMind and Isomorphic Labs.
  • Isomorphic Labs is a subsidiary of Alphabet that was launched from Alphabets DeepMind in 2021, with headquarters in London.

Oral Decitabine and Cedazuridine (ASTX727) Granted Orphan Drug Designation (ODD) by the European Commission for the Treatment of Acute Myeloid Leukemia (AML)

Retrieved on: 
목요일, 1월 6, 2022
Biotechnology, Pharmaceutical, Health, Oncology, ASTX727, Acute Myeloid Leukemia (AML), Astex, Otsuka, ASTX727, ACUTE MYELOID LEUKEMIA (AML), ASTEX, OTSUKA

Astex Pharmaceuticals, Inc. (Astex) announces today that the European Commission (EC) has granted orphan-drug designation (ODD) to the oral fixed dose combination of decitabine and cedazuridine (ASTX727) for the treatment of Acute Myeloid Leukemia (AML)1.

Key Points: 
  • Astex Pharmaceuticals, Inc. (Astex) announces today that the European Commission (EC) has granted orphan-drug designation (ODD) to the oral fixed dose combination of decitabine and cedazuridine (ASTX727) for the treatment of Acute Myeloid Leukemia (AML)1.
  • ASTX727 is not approved for any indication in Europe and is not approved in any country for the treatment of AML.
  • ASTX727 is an orally administered, fixed-dose combination of the approved anti-cancer DNA hypomethylating agent, decitabine, together with cedazuridine, an inhibitor of cytidine deaminase (CDA)3, 4.
  • Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Rigetti Computing, a Global Leader in Full-Stack Quantum Computing, Announces Plans to Become Publicly Traded via Merger with Supernova Partners Acquisition Company II

Retrieved on: 
수요일, 10월 6, 2021
Cloud, Person, Growth, U.S. Department of Energy, Office of Inspector General, The Carlyle Group, Bessemer Venture Partners, Latham & Watkins, Industry, SEC, U.S. Securities and Exchange Commission, LLP, Failure, Proxy, Form, CEO, Securities & Exchange Commission of Pakistan, Prospectus, Amazon Web Services, NYSE, Clifton, Palantir Technologies, Astex, Risk, DARPA, Sale, Morgan Stanley, Hotwire, Acquisition, Terminology, Quantum, LA, Sidley Austin, Cooley LLP, Ancient history, Forward-looking statement, Government, Name, Standard Chartered, Blackstone, Adoption, Zillow, Suite, Partner, Computer, Keysight, COVID-19, U.S. Department of Defense Strategy for Operating in Cyberspace, Research, PIPE, NASA, Ampere Computing, Microscope, Security (finance), Financial services, Video game console, Management

BERKELEY, Calif., Oct. 6, 2021 /PRNewswire/ -- Rigetti & Co., Inc. ("Rigetti"), a pioneer in full-stack quantum computing, announced today it has entered into a definitive merger agreement with Supernova Partners Acquisition Company II, Ltd. ("Supernova II") (NYSE:SNII), a publicly traded special purpose acquisition company. When the transaction closes, the publicly traded company will be named Rigetti Computing, Inc. and its common stock is expected to be listed on the NYSE under the ticker "RGTI."

Key Points: 
  • BERKELEY, Calif., Oct. 6, 2021 /PRNewswire/ --Rigetti & Co., Inc. ("Rigetti"), a pioneer in full-stack quantum computing, announced today it has entered into a definitive merger agreement with Supernova Partners Acquisition Company II, Ltd. ("Supernova II") (NYSE:SNII), a publicly traded special purpose acquisition company.
  • Scalability has been among the largest hurdles to bringing quantum computing to market, and Rigetti introduced its scalable superconducting chips in June 2021.
  • The company has operated quantum computers over the cloud since 2017 and serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform.
  • The company designs and manufactures its chips in-house at Fab-1, the industry's only dedicated and integrated quantum device manufacturing facility.

Recro Reports Second Quarter 2021 Financial Results

Retrieved on: 
월요일, 8월 9, 2021
Credit, LIBOR, Excipient, Acquisition, Cancer, QP, Social, Growth, Risk, Review, Solution, Exercise, U.S. Securities and Exchange Commission, DuPont, ESG, Leadership, COVID-19, Securities Exchange Act of 1934, EBITDA, Blister, Therapy, Biotechnology, Security (finance), Credit agreements in South Africa, Clinical Trial Service Unit, Clinical trial, CDMO, Phrase, GAAP, Development, ID, CGMP, Securities Act of 1933, Conference, Employment, GLOBE, Economy of the European Union, NASD, Culture, Income, Food industry, Revenue, Athyrium, Patheon, Astex, DEA, Three Months Gone, Energy Independence and Security Act of 2007, CTS, Animal, Pharmaceutical industry, Management, Risk management, Bank, Lithium, Vaccine

EXTON, Pa., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD:REPH), a dedicated contract development and manufacturing organization (CDMO) solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today reported financial results for the second quarter and six months ended June 30, 2021.

Key Points: 
  • ET
    EXTON, Pa., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Recro; NASD:REPH), a dedicated contract development and manufacturing organization (CDMO) solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today reported financial results for the second quarter and six months ended June 30, 2021.
  • This is a very exciting time at Recro, and today, the company is pleased to report strong second quarter earnings.
  • And finally, during and subsequent to the second quarter, the company continued to expand and enhance the business through leadership and talent.
  • Financial Results for the Three Months Ended June 30, 2021
    At June 30, 2021, Recro had cash and cash equivalents of $45.7 million compared to $23.8 million as of the end of the prior fiscal year.

Janssen Highlights Commitment to Advancing Transformative Innovations in Oncology with Scientific Updates from Deep, Diverse Pipeline and Portfolio at ASCO and EHA Virtual Scientific Programs

Retrieved on: 
화요일, 6월 1, 2021
Johnson & Johnson, Health care, Companies, Health, Janssen Pharmaceuticals, Janssen, Astex, Pharmaceutical industry in China, Ortho-McNeil-Janssen

Immediately following ASCO, additional data will be featured during the European Hematology Association (EHA) Virtual Congress, June 9-17.

Key Points: 
  • Immediately following ASCO, additional data will be featured during the European Hematology Association (EHA) Virtual Congress, June 9-17.
  • A complete list of Janssen-sponsored abstracts scheduled for presentation during ASCO and EHA is available at the Janssen Oncology Virtual Newsroom .
  • In 2008, Janssen entered into an exclusive worldwide license and collaboration agreement with Astex Pharmaceuticals to develop and commercialize BALVERSA.
  • Janssen Research & Development, LLC and Janssen Biotech, Inc. are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Recro Enters Development Agreement With Astex Pharmaceuticals

Retrieved on: 
화요일, 5월 18, 2021
Astex, Otsuka Pharmaceutical, Contract manufacturing organization

b'EXTON, Pa., May 18, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (\xe2\x80\x9cRecro\xe2\x80\x9d; NASD: REPH ), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced the signing of a new development agreement with Astex Pharmaceuticals, Inc.\n\xe2\x80\x9cWe are excited to add Astex, a leading developer of novel therapeutics for cancer, to our growing list of CDMO customers,\xe2\x80\x9d said Bill Hirschman, vice president of sales and marketing for Recro.

Key Points: 
  • b'EXTON, Pa., May 18, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (\xe2\x80\x9cRecro\xe2\x80\x9d; NASD: REPH ), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced the signing of a new development agreement with Astex Pharmaceuticals, Inc.\n\xe2\x80\x9cWe are excited to add Astex, a leading developer of novel therapeutics for cancer, to our growing list of CDMO customers,\xe2\x80\x9d said Bill Hirschman, vice president of sales and marketing for Recro.
  • \xe2\x80\x9cThe support we have been engaged to provide represents the type of durable, trusted relationship we work every day to build with our customers.
  • We look forward to an ever expanding partnership and wish Astex continued success.\xe2\x80\x9d\nRecro (NASD: REPH ) is a contract development and manufacturing organization (CDMO) with capabilities from early feasibility to commercial manufacturing.
  • These forward-looking statements are based on information currently available to us, and we assume no obligation to update any forward-looking statements except as required by applicable law.\n'

Taiho Oncology and Astex Pharmaceuticals To Present Data In Myelodysplastic Syndromes at the 62nd ASH Annual Meeting and Exposition

Retrieved on: 
수요일, 12월 2, 2020
Taiho Pharmaceutical, Astex, Taiho, Japanese aircraft carrier Taihō, Pharmaceutical industry in China, Health, Ships

Results will be shared online as a poster presentation on December 6, 2020.

Key Points: 
  • Results will be shared online as a poster presentation on December 6, 2020.
  • The abstract for this presentation is available on the ASH website: https://ash.confex.com/ash/2020/webprogram/Paper139552.html
    Additional information can be found at Taiho Oncology's Medical Booth when the exhibit opens on December 5, 2020.
  • Advanced technology, dedicated researchers, and state of the art facilities are helping us to define the way the world treats cancer.
  • For more information about Taiho Oncology, please visit: https://www.taihooncology.com/us
    For more information about Taiho Pharmaceutical Co., Ltd., please visit: https://www.taiho.co.jp/en/
    For more information about Otsuka Holdings Co., Ltd., please visit: https://www.otsuka.com/en/
    For more information about Astex Pharmaceuticals, Inc. please visit: https://www.astx.com

Astex Pharmaceuticals Expands Clinical Evaluation of Oral Decitabine and Cedazuridine Tablets Through New Cooperative Research and Development Agreement (CRADA) with the U.S. National Cancer Institute (NCI)

Retrieved on: 
수요일, 10월 28, 2020
Oncology, Health, FDA, Other Health, Clinical trials, Pharmaceutical, Biotechnology, Otsuka Pharmaceutical, Drugs, Clinical medicine, Medicine, Orphan drugs, Nucleosides, Decitabine/cedazuridine, Triazines, Decitabine, Chemotherapy, Astex, INQOVI (decitabine and cedazuridine) 35mg/100mg tablets, Astex Pharmaceuticals, Otsuka Pharmaceutical and Taiho Oncology

The agreement calls for a range of new clinical and translational studies of oral decitabine and cedazuridine tablets as an anticancer agent to be conducted in collaboration with Astex.

Key Points: 
  • The agreement calls for a range of new clinical and translational studies of oral decitabine and cedazuridine tablets as an anticancer agent to be conducted in collaboration with Astex.
  • Oral decitabine and cedazuridine tablets offer a new treatment option for patients with MDS and CMML, said Mohammad Azab, president and chief medical officer of Astex.
  • We are delighted to be entering into this collaboration with NCI to investigate and broaden the evaluation of the clinical potential of oral decitabine and cedazuridine.
  • The CRADA will also include oral decitabine and cedazuridine tablets in the NCI myeloMATCH master trial aimed at evaluating therapies for the treatment of myeloid malignancies.

Astex Pharmaceuticals and MD Anderson Announce Strategic Collaboration to Accelerate Clinical Evaluation of Therapies for Patients with Leukemia

Retrieved on: 
화요일, 9월 8, 2020
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Health, Astex, Otsuka Pharmaceutical, Clinical trial, University of Texas MD Anderson Cancer Center, INQOVI (See https://www.inqovi.com), MD Anderson, Astex Pharmaceuticals, Otsuka Pharmaceutical and Taiho Oncology

The collaboration will combine MD Andersons clinical trials infrastructure and expertise with Astexs clinical pipeline products.

Key Points: 
  • The collaboration will combine MD Andersons clinical trials infrastructure and expertise with Astexs clinical pipeline products.
  • This collaboration with Astex will allow us to expand those studies with the ultimate goal of providing patients with oral drug combinations that have the potential of improving clinical outcomes.
  • Under the collaboration agreement, MD Anderson and Astex will design new clinical studies to be conducted at MD Anderson.
  • MD Anderson has been a collaborator with Astex on multiple clinical studies for our pipeline products, said Mohammad Azab, president & chief medical officer of Astex.